THC Global eyes CBD opportunities in New Zealand underpinned by easier access for patients
THC Global Group Ltd (ASX:THC) is continuing to progress its exclusive distribution of Endoca CBD (cannabidiol) products in New Zealand with shipment of products recently landed.
Access to CBD products in New Zealand is relatively straightforward, with patients able to seek a prescription for CBD products just as they can for any other prescription medicine without the need for government approvals on a case-by-case basis as was previously required.
As a result, New Zealand has, proportionally, a far larger immediately accessible patient population compared to Australia given the regulatory hurdles for supply of medicinal cannabis to patients in Australia.
CBDinfo.co.nz
In order to provide prescribers with the best available information on CBD products to assist in making decisions on prescribing them to patients, THC provided financial assistance to DATAPHARM, a healthcare company in New Zealand, to launch CBDinfo.co.nz.
CBDinfo is a platform providing medical practitioners relevant and evidenced information about the use, availability, and potential benefits and risks of using CBD products.
Since launch in June 2019, over 100 medical practitioners have enrolled.
Once enrolled, practitioners can access detailed information on efficacy and safety data, as well as details on how to prescribe CBD products.
Initial sales have been positive
THCs import and distribution process makes Endoca products available to all wholesalers in New Zealand, rather than a specialised subset or specific region.
InitialRead More – Source
